These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 30016148)

  • 1. Combined Analysis of Biparametric MRI and Prostate-Specific Antigen Density: Role in the Prebiopsy Diagnosis of Gleason Score 7 or Greater Prostate Cancer.
    Lee SJ; Oh YT; Jung DC; Cho NH; Choi YD; Park SY
    AJR Am J Roentgenol; 2018 Sep; 211(3):W166-W172. PubMed ID: 30016148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biparametric Magnetic Resonance Imaging-Derived Nomogram to Detect Clinically Significant Prostate Cancer by Targeted Biopsy for Index Lesion.
    Kim MJ; Park SY
    J Magn Reson Imaging; 2022 Apr; 55(4):1226-1233. PubMed ID: 34296803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prebiopsy Biparametric Magnetic Resonance Imaging Combined with Prostate-specific Antigen Density in Detecting and Ruling out Gleason 7-10 Prostate Cancer in Biopsy-naïve Men.
    Boesen L; Nørgaard N; Løgager V; Balslev I; Bisbjerg R; Thestrup KC; Jakobsen H; Thomsen HS
    Eur Urol Oncol; 2019 May; 2(3):311-319. PubMed ID: 31200846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk Stratification Among Men With Prostate Imaging Reporting and Data System version 2 Category 3 Transition Zone Lesions: Is Biopsy Always Necessary?
    Felker ER; Raman SS; Margolis DJ; Lu DSK; Shaheen N; Natarajan S; Sharma D; Huang J; Dorey F; Marks LS
    AJR Am J Roentgenol; 2017 Dec; 209(6):1272-1277. PubMed ID: 28858541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prebiopsy multiparametric MRI and PI-RADS version 2.0 for differentiating histologically benign prostate disease from prostate cancer in biopsies: A retrospective single-center comparison.
    Tosun M; Uslu H
    Clin Imaging; 2021 Oct; 78():98-103. PubMed ID: 33773450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of risk factors for determining the need for prostate biopsy in patients with negative MRI.
    Liang L; Qi F; Cheng Y; Zhang L; Cao D; Cheng G; Hua L
    Sci Rep; 2021 Mar; 11(1):6048. PubMed ID: 33723287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of PI-RADS Version 2 for Prediction of Upgrading in Biopsy-Proven Prostate Cancer With Gleason Score 6.
    Song W; Bang SH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Choi HY; Kim CK; Lee HM
    Clin Genitourin Cancer; 2018 Aug; 16(4):281-287. PubMed ID: 29550198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The performance of PI-RADSv2 and quantitative apparent diffusion coefficient for predicting confirmatory prostate biopsy findings in patients considered for active surveillance of prostate cancer.
    Nougaret S; Robertson N; Golia Pernicka J; Molinari N; Hötker AM; Ehdaie B; Sala E; Hricak H; Vargas HA
    Abdom Radiol (NY); 2017 Jul; 42(7):1968-1974. PubMed ID: 28258355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
    Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
    Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
    [No Abstract]   [Full Text] [Related]  

  • 10. Prebiopsy IMPROD Biparametric Magnetic Resonance Imaging Combined with Prostate-Specific Antigen Density in the Diagnosis of Prostate Cancer: An External Validation Study.
    Knaapila J; Jambor I; Perez IM; Ettala O; Taimen P; Verho J; Kiviniemi A; Pahikkala T; Merisaari H; Lamminen T; Saunavaara J; Aronen HJ; Syvänen KT; Boström PJ
    Eur Urol Oncol; 2020 Oct; 3(5):648-656. PubMed ID: 31501082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRI combined with PSA density in detecting clinically significant prostate cancer in patients with PSA serum levels of 4∼10ng/mL: Biparametric versus multiparametric MRI.
    Han C; Liu S; Qin XB; Ma S; Zhu LN; Wang XY
    Diagn Interv Imaging; 2020 Apr; 101(4):235-244. PubMed ID: 32063483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinically Significant Prostate Cancer Detection After a Negative Prebiopsy MRI Examination: Comparison of Biparametric Versus Multiparametric MRI.
    Gan JM; Kikano EG; Smith DA; Rao S; Podury R; Wang M; Durieux JC; Paspulati RM; Ponsky L; Ramaiya NH; Tirumani SH
    AJR Am J Roentgenol; 2022 May; 218(5):859-866. PubMed ID: 34817189
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of quantitative apparent diffusion coefficient parameters with prostate imaging reporting and data system V2 assessment for detection of clinically significant peripheral zone prostate cancer.
    Hassanzadeh E; Alessandrino F; Olubiyi OI; Glazer DI; Mulkern RV; Fedorov A; Tempany CM; Fennessy FM
    Abdom Radiol (NY); 2018 May; 43(5):1237-1244. PubMed ID: 28840280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate Imaging Reporting and Data System, Version 2, Assessment Categories and Pathologic Outcomes in Patients With Gleason Score 3 + 4 = 7 Prostate Cancer Diagnosed at Biopsy.
    Lim CS; McInnes MDF; Flood TA; Breau RH; Morash C; Thornhill RE; Schieda N
    AJR Am J Roentgenol; 2017 May; 208(5):1037-1044. PubMed ID: 28267359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI-RADS version 2 for prediction of pathological downgrading after radical prostatectomy: a preliminary study in patients with biopsy-proven Gleason Score 7 (3+4) prostate cancer.
    Woo S; Kim SY; Lee J; Kim SH; Cho JY
    Eur Radiol; 2016 Oct; 26(10):3580-7. PubMed ID: 26847042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Values of multiparametric and biparametric MRI in diagnosing clinically significant prostate cancer: a multivariate analysis.
    Feng X; Chen X; Peng P; Zhou H; Hong Y; Zhu C; Lu L; Xie S; Zhang S; Long L
    BMC Urol; 2024 Feb; 24(1):40. PubMed ID: 38365673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining Magnetic Resonance Diffusion-Weighted Imaging with Prostate-Specific Antigen to Differentiate Between Malignant and Benign Prostate Lesions.
    Han L; He G; Mei Y; Yu Q; Zhao M; Luo F; Cheng G; Liang W
    Med Sci Monit; 2022 Apr; 28():e935307. PubMed ID: 35459760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing prostate cancer accumulating model: combined PI-RADS v2 with prostate specific antigen and its derivative data.
    Lu YF; Zhang Q; Yao WG; Chen HY; Chen JY; Xu CC; Yu RS
    Cancer Imaging; 2019 May; 19(1):26. PubMed ID: 31122297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prebiopsy biparametric MRI: differences of PI-RADS version 2 in patients with different PSA levels.
    Choi MH; Lee YJ; Jung SE; Rha SE; Byun JY
    Clin Radiol; 2018 Sep; 73(9):810-817. PubMed ID: 29895386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can Apparent Diffusion Coefficient Values Assist PI-RADS Version 2 DWI Scoring? A Correlation Study Using the PI-RADSv2 and International Society of Urological Pathology Systems.
    Gaur S; Harmon S; Rosenblum L; Greer MD; Mehralivand S; Coskun M; Merino MJ; Wood BJ; Shih JH; Pinto PA; Choyke PL; Turkbey B
    AJR Am J Roentgenol; 2018 Jul; 211(1):W33-W41. PubMed ID: 29733695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.